DK3468965T3 - 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indol-forbindelser til behandling af cancer - Google Patents
1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indol-forbindelser til behandling af cancer Download PDFInfo
- Publication number
- DK3468965T3 DK3468965T3 DK17728990.7T DK17728990T DK3468965T3 DK 3468965 T3 DK3468965 T3 DK 3468965T3 DK 17728990 T DK17728990 T DK 17728990T DK 3468965 T3 DK3468965 T3 DK 3468965T3
- Authority
- DK
- Denmark
- Prior art keywords
- dihydro
- cancer treatment
- indol compounds
- tetrahydropyranyl
- carbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348457P | 2016-06-10 | 2016-06-10 | |
| PCT/US2017/035097 WO2017213919A1 (en) | 2016-06-10 | 2017-05-31 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3468965T3 true DK3468965T3 (da) | 2020-06-15 |
Family
ID=59031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17728990.7T DK3468965T3 (da) | 2016-06-10 | 2017-05-31 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indol-forbindelser til behandling af cancer |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9872853B2 (da) |
| EP (1) | EP3468965B1 (da) |
| JP (1) | JP6632746B2 (da) |
| KR (1) | KR102241258B1 (da) |
| CN (1) | CN109641881B (da) |
| AR (1) | AR108586A1 (da) |
| AU (1) | AU2017277833B2 (da) |
| BR (1) | BR112018072872A2 (da) |
| CA (1) | CA3027035C (da) |
| CL (1) | CL2018003543A1 (da) |
| CO (1) | CO2018013251A2 (da) |
| CR (1) | CR20180579A (da) |
| CY (1) | CY1123660T1 (da) |
| DK (1) | DK3468965T3 (da) |
| DO (1) | DOP2018000278A (da) |
| EA (1) | EA037419B1 (da) |
| EC (1) | ECSP19001734A (da) |
| ES (1) | ES2797981T3 (da) |
| HR (1) | HRP20200769T1 (da) |
| HU (1) | HUE050155T2 (da) |
| IL (1) | IL263497B (da) |
| JO (1) | JOP20170131B1 (da) |
| LT (1) | LT3468965T (da) |
| MA (1) | MA45224B1 (da) |
| MD (1) | MD3468965T2 (da) |
| ME (1) | ME03744B (da) |
| MX (1) | MX2018015275A (da) |
| MY (1) | MY197462A (da) |
| NZ (1) | NZ748500A (da) |
| PE (1) | PE20190378A1 (da) |
| PH (1) | PH12018502572A1 (da) |
| PL (1) | PL3468965T3 (da) |
| PT (1) | PT3468965T (da) |
| RS (1) | RS60322B1 (da) |
| SG (1) | SG11201809625RA (da) |
| SI (1) | SI3468965T1 (da) |
| TW (1) | TWI671294B (da) |
| UA (1) | UA122526C2 (da) |
| WO (1) | WO2017213919A1 (da) |
| ZA (1) | ZA201807688B (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| BR112018067964B1 (pt) | 2016-03-07 | 2024-01-16 | Enanta Pharmaceuticals, Inc | Composto, composição farmacêutica que o compreende e uso do referido composto |
| TWI811236B (zh) | 2017-08-28 | 2023-08-11 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| US20210179607A1 (en) * | 2017-11-01 | 2021-06-17 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| US20210002371A1 (en) * | 2017-12-21 | 2021-01-07 | Brian A. Sherer | Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2020036837A1 (en) * | 2018-08-17 | 2020-02-20 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors |
| TW202024093A (zh) | 2018-09-21 | 2020-07-01 | 美商安塔製藥公司 | 作為抗病毒劑之官能化雜環 |
| EP3877366A4 (en) * | 2018-11-06 | 2022-08-24 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS |
| EP3883570A4 (en) | 2018-11-21 | 2022-07-13 | Enanta Pharmaceuticals, Inc. | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN114105961B (zh) * | 2021-12-10 | 2023-09-12 | 海南梵圣生物科技有限公司 | 一种ido1抑制剂(ly-3381916)制备方法 |
| CN114213310B (zh) * | 2021-12-31 | 2024-02-23 | 中国药科大学 | 吲哚啉化合物及其衍生物、制备方法、药物组合物和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1618090A1 (en) * | 2003-04-11 | 2006-01-25 | Novo Nordisk A/S | 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| WO2006122150A1 (en) * | 2005-05-10 | 2006-11-16 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| US8536221B2 (en) * | 2008-02-07 | 2013-09-17 | Abbvie Inc. | Amide derivatives as positive allosteric modulators and methods of use thereof |
| CN104042611B (zh) * | 2008-07-08 | 2019-05-14 | 因塞特控股公司 | 作为吲哚胺2，3-双加氧酶的抑制剂的1，2，5-噁二唑 |
| NO2694640T3 (da) * | 2011-04-15 | 2018-03-17 | ||
| MX2015012056A (es) * | 2013-03-15 | 2015-12-16 | Squibb Bristol Myers Co | Inhibidores de indolamina-2,3-dioxigenasa (ido). |
| LT3125883T (lt) * | 2014-04-04 | 2020-10-26 | Iomet Pharma Ltd. | Indolo dariniai, skirti panaudoti medicinoje |
| AR102537A1 (es) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| US10898483B2 (en) * | 2015-12-23 | 2021-01-26 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
-
2017
- 2017-05-24 JO JOP/2017/0131A patent/JOP20170131B1/ar active
- 2017-05-24 AR ARP170101413A patent/AR108586A1/es unknown
- 2017-05-25 TW TW106117300A patent/TWI671294B/zh not_active IP Right Cessation
- 2017-05-31 MX MX2018015275A patent/MX2018015275A/es unknown
- 2017-05-31 PT PT177289907T patent/PT3468965T/pt unknown
- 2017-05-31 MA MA45224A patent/MA45224B1/fr unknown
- 2017-05-31 ES ES17728990T patent/ES2797981T3/es active Active
- 2017-05-31 SI SI201730252T patent/SI3468965T1/sl unknown
- 2017-05-31 BR BR112018072872-1A patent/BR112018072872A2/pt not_active Application Discontinuation
- 2017-05-31 RS RS20200623A patent/RS60322B1/sr unknown
- 2017-05-31 HU HUE17728990A patent/HUE050155T2/hu unknown
- 2017-05-31 PL PL17728990T patent/PL3468965T3/pl unknown
- 2017-05-31 WO PCT/US2017/035097 patent/WO2017213919A1/en active Application Filing
- 2017-05-31 ME MEP-2020-98A patent/ME03744B/me unknown
- 2017-05-31 DK DK17728990.7T patent/DK3468965T3/da active
- 2017-05-31 MY MYPI2018002369A patent/MY197462A/en unknown
- 2017-05-31 CA CA3027035A patent/CA3027035C/en active Active
- 2017-05-31 US US15/609,115 patent/US9872853B2/en active Active
- 2017-05-31 EP EP17728990.7A patent/EP3468965B1/en active Active
- 2017-05-31 US US16/307,612 patent/US10759786B2/en active Active
- 2017-05-31 CN CN201780035976.4A patent/CN109641881B/zh not_active Expired - Fee Related
- 2017-05-31 AU AU2017277833A patent/AU2017277833B2/en not_active Ceased
- 2017-05-31 EA EA201892479A patent/EA037419B1/ru unknown
- 2017-05-31 LT LTEP17728990.7T patent/LT3468965T/lt unknown
- 2017-05-31 NZ NZ748500A patent/NZ748500A/en not_active IP Right Cessation
- 2017-05-31 MD MDE20190462T patent/MD3468965T2/ro unknown
- 2017-05-31 SG SG11201809625RA patent/SG11201809625RA/en unknown
- 2017-05-31 PE PE2018003199A patent/PE20190378A1/es unknown
- 2017-05-31 JP JP2018563823A patent/JP6632746B2/ja not_active Expired - Fee Related
- 2017-05-31 CR CR20180579A patent/CR20180579A/es unknown
- 2017-05-31 KR KR1020187035215A patent/KR102241258B1/ko active IP Right Grant
- 2017-05-31 UA UAA201811735A patent/UA122526C2/uk unknown
-
2018
- 2018-11-15 ZA ZA2018/07688A patent/ZA201807688B/en unknown
- 2018-12-04 IL IL263497A patent/IL263497B/en active IP Right Grant
- 2018-12-06 PH PH12018502572A patent/PH12018502572A1/en unknown
- 2018-12-06 CO CONC2018/0013251A patent/CO2018013251A2/es unknown
- 2018-12-10 DO DO2018000278A patent/DOP2018000278A/es unknown
- 2018-12-10 CL CL2018003543A patent/CL2018003543A1/es unknown
-
2019
- 2019-01-09 EC ECSENADI20191734A patent/ECSP19001734A/es unknown
-
2020
- 2020-05-12 HR HRP20200769TT patent/HRP20200769T1/hr unknown
- 2020-06-05 CY CY20201100508T patent/CY1123660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3468965T3 (da) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indol-forbindelser til behandling af cancer | |
| DK3580211T3 (da) | 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3582853T3 (da) | Cykliske dinukleotidforbindelser til behandling af cancer | |
| DK3431105T3 (da) | Medicinsk sammensætning til behandling af cancer | |
| DK3478286T3 (da) | Fremgangsmåder til behandling af ovariecancer | |
| DK3559265T3 (da) | Fremgangsmåde til behandling af polynukleotider | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| DK3377516T3 (da) | Sammensætning til behandling af cancer | |
| DK3374359T3 (da) | Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer | |
| DK3389778T3 (da) | Indretning til fotodynamisk behandling | |
| DK3509893T3 (da) | Fremgangsmåde til roaming | |
| DK3294700T3 (da) | Fremgangsmåde til fremstilling af limonen-4-ol | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3353177T3 (da) | Tricykliske heterocykler til behandling af cancer | |
| DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
| BR112018005409A2 (pt) | terapêutica de glicodirecionamento. | |
| DK3393468T3 (da) | Fremgangsmåder til behandling af en immundefektsygdom | |
| DK3318115T3 (da) | Maskine til behandling af svinegylle | |
| DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3303616T3 (da) | Fremgangsmåder til prognose af prostatakræft | |
| ITUA20163081A1 (it) | Tutore gamba-piede alto di scarico. | |
| DK3386997T3 (da) | Monomaleimid-funktionaliserede platinforbindelser til cancerterapi |